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Pancreatic disease has onset in utero in humans with
cystic fibrosis (CF), and progresses over time to com-
plete destruction of the organ. The exact mechanisms
leading to pancreatic damage in CF are incompletely
understood. Inflammatory cells are present in the
pancreas of newborn pigs with CF (CF pigs) and hu-
mans, which suggests that inflammation may have a
role in the destructive process. We wondered whether
tissue inflammation and genes associated with in-
flammatory pathways were increased in the pancreas
of fetal CF pigs [83 to 90 days gestation (normal pig
gestation is114 days)] and newborn pigs. Compared
with fetal pigs without CF (non-CF pigs), in fetal CF
pigs, the pancreas exhibited patchy inflammation
and acinar atrophy, with progression in distribution
and severity in neonatal CF pigs. Large-scale tran-
script profiling revealed that the pancreas in fetal and
newborn CF pigs exhibited significantly increased ex-
pression of proinflammatory, complement cascade,
and profibrotic genes when compared with fetal and
newborn non-CF pigs. Acinar cells exhibited in-
creased apoptosis in the pancreas of fetal and new-
born CF pigs. -Smooth muscle actin and transform-
ing growth factor 1 were increased in both fetal and
newborn CF pig pancreas, suggesting activation of
profibrotic pathways. Cell proliferation and mucous
cell metaplasia were detected in newborn, but not fetal,
CF pigs, indicating that they were not an initiator of
pathogenesis but a response. Proinflammatory, comple-
ment cascade, proapoptotic, and profibrotic pathways
are activated in CF pig pancreas, and likely contribute tothe destructive process. (Am J Pathol 2012, 181:499–507;
http://dx.doi.org/10.1016/j.ajpath.2012.04.024)
Cystic fibrosis (CF) is caused by mutations in the gene
encoding the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) anion channel.1 This life-threaten-
ing disease involves multiple organ systems (eg, sweat
ducts, airway, pancreatic duct, intestines, biliary tree,
and vas deferens). The greatest morbidity and mortality
in CF stem from lung disease.2–4
Because pancreatic function studies in humans with
CF showed the presence of acidic, concentrated, and
dehydrated pancreatic secretions,5–9 and autopsy find-
ings were consistent with plugging of acinar and ductal
lumens,10–18 it is generally agreed that CFTR dysfunction
leads to defective pancreatic fluid and bicarbonate se-
cretion and plugging. As the disease progresses, the
exocrine pancreas is replaced by fatty infiltration and
fibrosis10,12–14,16,17 and completely loses its function in
85% of patients with CF.19–24 Although pancreatic dis-
ease is nearly universal in CF, the time of disease onset
and the stages between lumen-occluding secretions and
pancreatic damage are not well understood. Pancreatic
insufficiency has a major effect on growth, nutrition, and
lung disease,19,25,26 and currently there are no treat-
ments to halt the progression of pancreatic disease in CF.
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creatic involvement can be accomplished only with better
understanding of the disease mechanisms that evolve in
utero and immediately after birth.
Because the pancreas is not easily accessible in hu-
mans, CFTR gene knockout mouse models have been
developed to study the mechanisms of pancreatic dis-
ease in CF.27,28 Inflammation,29 defective acinar cell en-
docytosis,30–33 and an imbalance in membrane essential
fatty acids34 have all been suggested as potential mech-
anisms of pancreatic disease in the mouse model of CF.
However, pathologic changes in the pancreas are mild in
mice with CF, and do not progress to fibrosis and organ
failure as typically observed in humans with CF.11–16
In the present study, we investigated the mechanisms
of pancreatic damage in newborn and 83- to 90-day-old
fetal pigs (pig gestation is 114 days) with CFTR null35
and homozygous F508 mutations.36 We found that the
pancreatic disease progressed over time in the pigs with
CF (CF pigs) and that proinflammatory, complement cas-
cade, proapoptotic, and profibrotic pathways were acti-
vated in CF compared with non-CF at both time points.
Tissue remodeling (eg, mucous cell metaplasia and duct
cell proliferation) was found in the newborn CF pig pan-
creas but not in fetuses, suggesting that these processes
do not drive early disease pathogenesis but are a late
response to ongoing tissue damage. These findings sug-
gest that the pathogenesis of progressive pancreatic dam-
age in CF may be, in part, a consequence of the activation
and progression of the proinflammatory, proapoptotic, pro-
fibrotic, and complement cascade pathways.
Materials and Methods
Animals
All studies were approved by the University of Iowa An-
imal Care and Use Committee. CF (CFTR/ and
CFTRF508/F508) and non-CF (CFTR/, CFTR/, and
CFTR/F508) piglets were obtained from Exemplar Ge-
netics (Sioux Center, IA) and studied within 24 hours after
birth. Fetuses (83 to 90 days’ gestation [pig gestation is
114 days]) were collected via cesarean section. The
83- to 90-day gestation point was chosen because that is
when the pancreas has a well-developed architecture
and is able to produce pancreatic enzymes.37
Total RNA Extraction
Pancreas was collected immediately after euthanasia,
sectioned into 1- to 2-mm pieces, immersed in a stabilizer
reagent (RNAlater; Ambion, Inc., Austin, TX), and snap
frozen in liquid nitrogen. Samples were used immediately
or stored at 80°C until use. Tissues were homogenized
briefly using a rotor/stator-type tissue homogenizer
(model 780CL-04; Bio Spec Products, Inc., Bartlesville,
OK) at 18,000 to 22,000 rpm at 4°C. The pancreatic
homogenate was centrifuged at 2000 rpm for 10 minutes,
and the supernatant was collected. Total RNA was ex-
tracted from the supernatant using the PerfectPure RNA
Fibrous Tissue Kit (catalog No. 2900303; 5 PRIME GmbH,Hamburg, Germany). RNA concentration was measured
via optical density at a 260-nm wavelength using a Nano-
Drop 1000 Spectrophotometer (ThermoFisher Scientific,
Inc., Wilmington, DE). The RNA quality was assessed
via electrophoresis using an Agilent 2100 Bioanalyzer
(Agilent Technologies, Inc., Santa Clara, CA).
Microarray and Analysis Protocol
The sample population included four non-CF (one
CFTR/ and three CFTR/F508) and four CF
(CFTRF508/F508) pancreata from 83- to 90-day-old fe-
tuses, and eight non-CF (four CFTR/ and four
CFTR/) and four CF (CFTR/) pancreata from new-
born pigs. Only samples with an RNA integrity number
higher than 7.0 on the Agilent Bioanalyzer (Agilent Tech-
nologies) were processed further. Two micrograms total
RNA was used to generate biotinylated complementary
RNA using the GeneChip one-cycle target labeling kit
(Affymetrix, Inc., Santa Clara, CA) according to the man-
ufacturer’s recommended protocols, and was hybridized
to the Affymetrix Porcine GeneChip (23,937 probe sets
that interrogate 23,256 transcripts from 20,201 Sus
scrofa genes). The arrays were washed, stained, and
scanned using a Fluidics Station (model 450) and scan-
ner (model 3000) (both from Affymetrix), and data were
collected using GeneChip operating software (version
1.4; Affymetrix) using the manufacturer’s recommended
protocols. The following tools were used to analyze the
microarray data: Gene Pattern38 (unsupervised hierarchi-
cal clustering), Partek Genomics Suite (2008, revision
6.3; Partek, Inc., St. Louis, MO) (one-way analysis of
variance; ANOVA), GSEA (Gene Set Enrichment Analy-
sis),39 and DAVID (Database for Annotation, Visualization
and Integrated Discovery; National Institute of Allergy
and Infectious Diseases, National Institutes of Health,
Bethesda, MD).40 Use of these tools to analyze microar-
ray data has been previously described.41
Quantitative RT-PCR
RNA from eight non-CF (CFTR/ and CFTR/F508) and
seven CF (CFTRF508/F508) fetal pancreata, and eight
non-CF (CFTR/) and seven CF (one CFTRF508/F508
and six CFTR/) newborn pancreata were treated using
a DNase1 kit (New England BioLabs, Inc., Ipswich, MA).
One microgram RNA was used to generate first-strand
cDNA using SuperScript II (Invitrogen Corp., Carlsbad,
CA), and oligo-dT and random hexamer primers. GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) was used
as a control. Primer-probe sequences were ordered from
Integrated DNA Technologies, Inc. (IDT, Coralville IA). All
reactions were set up using TaqMan Fast Universal PCR
Master Mix (Applied Biosystems, Inc., Foster City, CA)
and run on the 7900HT Real-Time PCR system (Applied
Biosystems). All experiments were performed in quadrupli-
cate using 56-FAM (single isomer of 6-carboxyfluorescein),
and 3IABlkFQ (Iowa Black FQ dark quencher). Primer and
probe sequences were as follows: TGFB1, forward 5=-
AGGGCTACCATGCCAATTTCT-3=, reverse 5=-CGGGTT-
GTGCTGGTTGTACA-3=, probe 5=-/56-FAM/CCTAGACA-
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ward 5=-CCGTGTCAACATGACTTCCAA-3=, reverse 5=-GC-
CTCACAGAGAGCTGCAGAA-3=, probe 5=-/56-FAM/CTG-
TTGCCTTCTTGGCAGTTTTCCTGC/3IABlk-FQ/-3=; NFKB1,
forward 5=-CTGGCAGCTCTCCTCAAAGC-3=, reverse
5=-CACGAGTCATCCAGGTCATACAG-3=, probe 5=-/56-
FAM/CTCAAAGTTCTCCACCAGGGGATCTGCTC/3IABlk-
FQ/-3=; C3, forward 5=-CAAGAAATGATTGGTGGCTTCAA-3=,
reverse 5=-GACCTGTGGTTCACAGATGTCTTT-3=, probe
5=-/56-FAM/AGCCTTTGTTCTCATCGCGCTGCA/3IABlk-
FQ/-3=; CFB, forward 5=-TGATCAGGCTCTCGAAAAAGC-
3=, reverse 5=-GGTTGTCAGAGGAAGCCTCAGA-3=, probe
5=-/56-FAM/ATCAGGCCCATTTGTCTCCCCTGC/3IABlk-
FQ/-3=; C1QB, forward 5=-CCGGCCTTTACTACTTCACCT-
ATC-3=, reverse 5=-CGGCCACGCATGAGGTT-3=, probe 5=-/
56-FAM/CGCACAGGTTCCCTCGAGAGCTG/3IABlk-FQ/-3=;
GAPDH, forward 5=-GGCATGGCCTTCCGTGT-3=, reverse 5=-
GCCCAGGATGCCCTTGAG-3=, probe 5=-/56-FAM/
CCTGCTTCACCACCTTCTTGATGTCATCAT/3IABlk-FQ/-3=.
IHC Staining
Pancreata were harvested immediately after necropsy and
placed in 10% neutral buffered formalin for 48 to 96 hours,
and were routinely processed, embedded, sectioned, and
stained with H&E or amylase-pretreated PAS.36
Ki-67
Ki-67 IHC was performed as previously described.42 In
brief, between sequential incubations, sections were inter-
mittently rinsed with primary antibody (rabbit anti-Ki-67
monoclonal antibody, 1:800 dilution, overnight at 4°C), a
secondary antibody (Rabbit Envision HRP System), and
chromogen diaminobenzidine (DAB Plus for 5 minutes and
enhancer for 3 minutes) (all agents from Dako, Carpinteria,
CA). Morphometric analysis was performed on 5 to 10 ran-
dom sections of pancreas. Cells of ductuloacinar units were
counted (mean, 200 cells per pancreas), and each nu-
cleus was noted as stained or unstained for enumeration of
the cellular percentage of Ki-67 immunostaining.
Caspase-3
Caspase-3 IHC was performed as previously de-
scribed.43 In brief, sections were intermittently rinsed be-
tween sequential incubations with primary antibody (rab-
bit monoclonal antibody against activated caspase-3,
No. 9664L; Cell Signaling Technologies, Inc., Beverly,
MA) and a secondary antibody (Rabbit Envision HRP
System), and chromogen diaminobenzidine (DAB Plus
for 5 minutes and enhancer for 3 minutes) (both from
Dako). Morphometric analysis was performed on 5 to 10
random sections of pancreas. Ductuloacinar units (200 to
250 cells per pancreas) were counted along with positive
ductuloacinar immunostaining. Particular attention was
given to exclude caspase-3 immunostaining, commonly
associated with infiltrative leukocytes,44 from the morpho-
metric analysis. Total ductuloacinar units, along with im-
munostained ductuloacinar units, were enumerated togive the caspase-3 immunostaining index (percentage of
stained cells to total cells counted).
-SMA
Paraffin-embedded tissue sections were cut into 4-m
pieces, hydrated through a series of alcohol baths, and
rinsed (1 Dako Buffer). Endogenous peroxidase was
quenched with 3% H2O2 for 8 minutes, followed by rins-
ing. Tissues were incubated with primary antibody
(mouse monoclonal antibody, anti--smooth muscle actin
[-SMA] antibody, catalog No. A2547; Sigma-Aldrich, St.
Louis, MO), and rinsed, and then with secondary anti-
body (Mouse Envision HRP System, Dako), and rinsed,
and stained with chromogen diaminobenzidine (DAB
Plus for 5 minutes and enhancer for 3 minutes; Dako).
Slides were counterstained with hematoxylin for 1 minute
(Surgipath Medical Industries, Richmond, IL), rinsed, de-
hydrated through a series of alcohol and xylene baths,
coverslipped, and stored.
Statistical Analyses
Data are given as the mean (SD) of individual data points.
Statistical significance between groups was determined
using Student’s t-test or one-way ANOVA. The P values
generated for the microarray analyses were not corrected
for multiple comparisons. For the microarray studies, a
highly stringent cutoff of P  0.01 was considered signif-
icant because the list of differentially expressed genes
with P  0.05 was large.
Results
CF Pancreatic Lesions Progress From 83 to 90
Days Gestation to Birth (114 Days)
To determine how pancreatic lesions progress over time
in CF pigs, we compared the pancreatic histologic find-
ings in the newborn and 83- to 90-day-old fetal CF and
non-CF pigs. The fetal CF pancreata exhibited a patchy
loss of zymogen-filled acini (Figure 1), often with concur-
rent inflammation and tissue destruction. Inflammation
was composed of loose lymphoid (lymphocytes and
plasma cells) interstitial aggregates, and neutrophils and
macrophages were scattered in the lumens of affected
acini and ducts. At birth, CF pig pancreata had lost most
zymogen-filled acini; however, remnants of degenerative
pancreas were detected in most of the sections (Figure 1).
The newborn CF pig pancreas exhibited duct prolifera-
tion, expansion of interlobular connective tissue, and
scattered inflammatory cell aggregates. These findings
confirm that, as in humans, pancreatic lesions began in
utero in the CF pigs, and progressed over time to near
destruction of the organ,10,14,15 with mixed inflammatory
infiltrates detected in both fetal and neonatal pigs.
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Pancreas in CF
We next examined the transcriptional profile to identify
the genes that were differentially expressed between the
pancreata of CF and non-CF fetal and newborn pigs.
Unsupervised hierarchical clustering38,41 of 12 newborn
and 8 fetal samples revealed segregation of the gene
expression profiles of the newborn and fetal samples by
genotype (Figure 2A). Furthermore, within each develop-
mental stage, the samples also clustered by genotypes
(Figure 2A). By one-way ANOVA (Partek Genomics
Suite),41 there were many differentially expressed genes
between the CF and non-CF pancreas samples. Using as
significance P  0.01, 2586 genes were differentially ex-
pressed in the fetal CF pancreas, and 4411 genes were
differentially expressed in the newborn CF pancreas (Figure
2B). Analysis of the differentially expressed genes using
DAVID40,41 identified 27 pathways and 18 pathways with
significant genotype-dependent differences in the fetal and
newborn pancreata, respectively (P  0.05) (Table 1). To
further elucidate the gene pathways that were altered in the
CF pancreas, the data were analyzed using GSEA.39,41,45
With a false discovery rate of 0.25, 1327 pathways were
differentially expressed in the fetal CF samples, and 1576
pathways were differentially expressed in the newborn CF
samples (Table 1). The large number of differentially ex-
pressed pathways using a low stringency significance level
(DAVID, P  0.05; GSEA, false discovery rate 0.25) re-
flects the high number of genes exhibiting significant
changes in expression, as observed in the ANOVA data
sets. Together, these data indicate a global change in the
pancreas transcriptome brought about by the absence of
Figure 1. CF and non-CF pancreata at 83 to 90 days gestation and at birth.
Eosinophilic zymogen material is abundant in all pancreatic acini in non-CF
animals (eosinophilic staining). At 83 to 90 days gestation, CF pancreata
exhibit reduced zymogen-filled mature acini (black arrows), which was
associated with increased acini plugging and degeneration by luminal eosi-
nophilic zymogen secretions (red arrow). This eventually results in further
loss of normal zymogen-filled acini by birth (arrow). While less extensive in
fetal versus neonatal CF pancreas, discrete patchy aggregates of lymphoid
inflammation (arrowheads) expand the interstitium, with scattered neutro-
phils and macrophages occasionally seen in the lumen of adjacent ducts and
acini, similar to the localization pattern of inflammation previously described
in CF pig pancreas.36,47 H&E. Scale bar  100 m.functional CFTR.Inflammation Is an Early Event in CF Pig
Pancreatic Disease
Similar to histopathologic observations35,36,46 and flow
cytometry studies47 that showed increased inflammation
of mixed cell type in the CF pig pancreas, GSEA revealed
enrichment of inflammatory gene sets in the CF samples
at both developmental stages. To further identify the na-
Figure 2. Loss of CFTR function alters the transcriptome in the CF pancreas.
A: Unsupervised hierarchical clustering in 8 fetal and 12 newborn CF samples
reveals significant differences in the transcriptome profile of CF and non-CF
samples at fetal and newborn stages. B: One-way ANOVA reveals differen-
tially expressed genes in the fetal and newborn CF samples (P 0.01). C and
D: Quantitative RT-PCR of the fetal and newborn pancreas samples shows
the relative abundance of genes. Each bar represents data from eight non-CF
and seven CF samples tested in quadruplicate. Error bars indicate mean (SD).
*P  0.01, CF versus non-CF.
ery; FD
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prepared custom gene sets that addressed the following
biological processes: i) response to injury, ii) inflamma-
tory response, iii) host-defense response, and iv) innate
immunity (see Supplemental Table S1 at http://ajp.
amjpathol.org). Significant enrichment of these gene sets
was observed in both fetal and newborn CF pancreata
(Table 2),48 with greater fold increases in the newborn
samples compared with the fetal samples. To further
substantiate these findings, we assessed the mRNA
abundance of the proinflammatory markers IL-8 and the
nuclear factor NF-B p105 subunit using quantitative RT-
PCR. We found a significant increase in both of these
mRNAs in the fetal and newborn CF samples (Figure 2, C
and D). These results further support the activation of
proinflammatory genes in the CF pig pancreas in utero. In
addition, the number of activated proinflammatory genes
increased over time as the lesions progressed.
Complement Cascade Pathways Are Activated
in CF Pig Pancreas Starting in Utero
An intriguing observation was the significant increase in
complement pathways at stringent significance levels in
both the fetal and neonatal CF pig pancreata, as ana-
lyzed using DAVID (P  0.01) and GSEA (false discovery
rate 0.05) (Table 1). To better understand the involve-
ment of complement pathways in the CF pig pancreas,
we built custom gene sets for i) complement activation,
Table 1. Pathway Analysis (GSEA) of Differentially Expressed G
Pancreas GSEA
DA
P  0.01
Fetal Enriched in CF 18
Enriched in Non-CF 0
Newborn Enriched in CF 6
Enriched in Non-CF 0
DAVID, Database for Annotation, Visualization, and Integrated Discov
Table 2. Gene Set Enrichment Analysis of Fetal and Newborn Pa
Custom gene sets
No. of
Genes*
Fetal pa
No. of
enriched
genes† NES
Response to injury 688 310 1.54
Inflammatory response 251 125 1.44
Host defense response 283 136 1.51
Innate immunity 99 46 1.55
Complement activation 37 25 1.7
Classical complement pathway 27 19 1.68
Alternative complement pathway 32 21 1.75
Induction of apoptosis 268 104 1.31
Tissue remodeling 72 29 1.37
Fibroblast proliferation 45 24 1.34
Endothelial cell proliferation 47 22 1.37
Adipose tissue development 76 28 1.4
*Number of genes represents the genes present in the gene set anno
†Number of enriched genes-represents genes from the total list that were en
FDR, false discovery rate (FDR 0.25 is considered significant); NES, normaii) classical complement pathway, iii) alternative comple-
ment pathway, and iv) induction of apoptosis (Table 2;
see also Supplemental Table S1 at http://ajp.amjpathol.
org). We investigated apoptosis because this process
often accompanies complement-mediated cell destruc-
tion.49 All four gene sets were significantly enriched in the
CF pig pancreas at both time points. Furthermore, these
pathways were significantly more enriched in the new-
born CF samples than in fetal samples. Using quantitative
RT-PCR, we confirmed a significant increase in the fol-
lowing complement genes in both fetal and newborn CF
samples: complement factor 1 (C1QB), complement fac-
tor 3 (C3), and complement factor B (CFB) (Figure 2, C
and D). These data show that key genes in the comple-
ment pathway are overexpressed in the CF pig pancreas
starting in utero.
Apoptosis Is Increased in Fetal and Newborn
CF Pig Pancreas
To further investigate the activation of apoptotic path-
ways in the CF pig pancreas, we immunostained fetal
and newborn CF and non-CF pig pancreata for activated
caspase-3, a key enzyme in apoptotic cell death. Scat-
tered acini exhibited immunoreactive acinar cells, and
these affected acini were sometimes associated with leu-
kocytes near or infiltrative into the acinus or by luminal
filling or obstruction by zymogen material. We observed a
significant increase in activated caspase-3 immunostain-
AVID) in Fetal and Newborn Pig Pancreas Samples
ne sets GSEA gene sets
P  0.05 FDR  0.05 FDR  0.25
27 0 1327
0 0 0
18 6 1576
0 0 0
R, false discovery rate; GSEA, Gene Set Enrichment Analysis.
Samples48
samples Newborn pancreas samples
Description of
change
No. of
enriched
genes† NES FDR
Description of
change
Enriched in CF 476 1.91 0.09 Enriched in CF
Enriched in CF 84 1.88 0.147 Enriched in CF
Enriched in CF 137 1.94 0.13 Enriched in CF
Enriched in CF 45 1.86 0.025 Enriched in CF
Enriched in CF 17 1.9 0.005 Enriched in CF
Enriched in CF 13 1.76 0.004 Enriched in CF
Enriched in CF 17 1.77 0.007 Enriched in CF
Enriched in CF 144 1.57 0.01 Enriched in CF
Enriched in CF 29 1.84 0.004 Enriched in CF
Enriched in CF 21 1.55 0.03 Enriched in CF
Enriched in CF 18 1.57 0.05 Enriched in CF
Enriched in CF 27 1.77 0.04 Enriched in CF
the porcine array.enes (D
VID gencreas
ncreas
FDR
0.02
0.03
0.02
0.03
0.02
0.02
0.02
0.06
0.07
0.06
0.13
0.03
tated in
riched in that gene set.
lized enrichment score.
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AJP August 2012, Vol. 181, No. 2ing of acinar cells in the CF pig pancreas samples at both
fetal and newborn stages (Figure 3). Infiltrative neutro-
phils also commonly exhibited activated caspase-3 stain-
ing, as has been described,42 and these were excluded
from the morphometric analysis. This finding suggests
Figure 3. Apoptosis is increased in both fetal and newborn CF pig pancreas.
Activated caspase-3 staining (arrows) of non-CF and CF pig pancreas at 83
days gestation and in newborn pigs (IHC). Caspase-3 index was measured in
6 non-CF and 3 CF fetuses (left graph) and 10 non-CF and 18 CF newborn
pigs (right graph), which show increased immunostaining in the CF pig
pancreas at both time points. *P  0.05. Scale bar  35 m.
Figure 4. Top panels: Fetal and newborn Non-CF pig pancreata showing a
normal duct that is empty and one filled by normal secretions, respectively.
Mucous cell metaplasia is a late event in pancreatic disease in CF. Left panels:
Mucous cell change in the duct epithelium is lacking in non-CF and CF pancreata
at 90-days gestation (arrows). Bottom right panel: In the newborn pigs with
CF, obstructed ducts were often distended with mucus (magenta area), and the
mucous cells were prominent in the epithelium (arrows). Mucous cell meta-
plasia was not detected in non-CF neonatal pig pancreas. dPAS stain.
Scale bar  45 m.that apoptotic pathways are activated in the CF pig pan-
creas starting in utero.
Tissue Remodeling Is a Late Event in CF Pig
Pancreatic Disease
Intralobular duct mucous cell metaplasia has been de-
scribed in the pancreas in children and adults with
CF,15,17 possibly as a late event. We examined fetal and
newborn CF and non-CF pig pancreata for the presence
of mucous cell metaplasia in obstructed ducts; however,
this was found only in the pancreata of CF newborn pigs,
not fetuses (Figure 4), which suggests that mucous cell
metaplasia is a late event in CF pancreatic disease.
We then examined whether the myofibroblastic
changes and cell proliferation typically found in the pan-
creas of humans with CF14,16 were present in the new-
born and fetal pigs with CF. We used IHC staining to
detect differences in cell proliferation (Ki-67 antigen),
along with morphometric analysis. Fetal pancreata in
both groups similarly exhibited high levels of cellular pro-
liferation, consistent with a growing fetus. In contrast,
cellular proliferation in neonatal pancreata was generally
reduced; however, the newborn pancreata were signifi-
cantly more proliferative in the CF versus the non-CF
group (Figure 5). This finding was also supported by the
custom GSEA data that showed significant enrichment of
pathways associated with proliferation in the newborn CF
pig pancreas but not in the fetal samples (Table 2).
We then stained CF and non-CF fetal and newborn pig
pancreata for -SMA to detect early fibroplasia (Figure 6). In
Figure 5. Increased cell proliferation in the newborn CF pig pancreas. Ki-67
immunostaining is increased in newborn CF pig pancreas (n 20) compared
with non-CF pancreas (n  10) (*P  0.001) but is similar between fetal pig
groups (CF, n  4; non-CF, n  6). Ki-67-positive cells are often associated
with proliferative ductuloacinar units. Scale bar  100 m.the non-CF animals, immunoreactive cells were uncom-
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periductular cells. In the fetal CF pig pancreas, there was
enhanced and patchy immunostaining in expanded in-
teracinar interstitial spaces. In the newborn CF pigs,
-SMA staining was prominent in the myofibroblasts
around the proliferative ducts. Consistent with these find-
ings, transforming growth factor 1 mRNA levels were
significantly higher in the pancreata of newborn CF pigs
compared with CF fetuses (Figure 2, C and D). These
findings are consistent with the development of tissue re-
modeling from the fetal to the neonatal period, and confirm
the progressive nature of pancreatic disease in CF.
Discussion
In the present study, pancreatic lesions started in utero in
CF pigs and progressed over time, in concordance with
previous autopsy studies in humans with CF.10,14,15 We
detected activation of proinflammatory, complement cas-
cade, and apoptotic pathways early in development,
whereas components of tissue remodeling (mucous cell
metaplasia, duct proliferation, and increased myofibro-
blast activity) were detected at birth and constituted later
events. Our observations suggest that mucous cell meta-
plasia and duct cell proliferation do not have a primary role
in the pathogenesis of pancreatic disease in CF but are a
late response to inflammation and tissue destruction.
A major advantage of the present study was the avail-
ability of the fetal and newborn pancreas samples, which
enabled us to study the timing of onset and the mecha-
nisms that contribute to inflammation, tissue destruction,
and injury in a pristine environment lacking microbial and
environmental insults. Because the pancreas cannot be
easily obtained from human fetuses or infants and young
children with CF at early stages of pancreatic disease,
such a study is not possible in humans. CF mice have
Figure 6. CF pig pancreas exhibit increased -SMA immunostaining in fetal
pancreas at 90 days gestation and in newborn pigs. Top panels: In non-CF
pig pancreas, -SMA staining is detected, as normally expected, surrounding
the ducts (arrows) and vessels (arrowheads). Bottom panels: At 90-days
gestation, CF pancreas exhibits patchy mild to moderate staining adjacent to
relatively unaffected exocrine tissue, whereas neonatal CF pancreas demon-
strate widespread -SMA staining surrounding proliferative and dilated ducts.
Scale bar  350 m.limited applicability for such studies because the pan-creas is mildly involved.27,28 With pancreatic involvement
similar to pancreatic disease in humans, the CF pig
model enables access to tissues at all stages of the
disease and provides the opportunity for mechanistic
studies of the pathogenesis of pancreatic disease.
We observed a significant difference in the global
gene expression profile between CF and non-CF pan-
creata in both fetal and neonatal pigs. The number of
activated proinflammatory, complement cascade, apop-
totic, and profibrotic pathway genes were higher in the
newborn CF pancreata compared with fetal pancreata,
consistent with the disease progression. These findings
support the hypothesis of early activation and contribu-
tion of these pathways in pancreatic disease in CF.
We found that many proinflammatory pathways were
activated in the pancreas of CF pigs starting in the fetal
period. These findings are consistent with histopatho-
logic observations35,36,46 and flow cytometry studies47 in
the newborn CF pig pancreas. Together with the pres-
ence of inflammatory cell infiltrates in the human CF pan-
creas10,13,15 and heightened inflammatory response to
cerulein hyperstimulation in CF mice,29 our data suggest
that inflammation may have a significant role in the dis-
ease process. Although inflammatory cell infiltrates are
well-known features of pancreatic disease in humans with
CF,10,13,15 the earliest studies in humans suggest that the
ductuloacinar plugging may be the first histopathologic
finding in the CF pancreas.11,18 Plugging and obstruction
may trigger an inflammatory response in the CF pancreas
that leads to tissue destruction and organ failure. Analy-
sis of earlier time points in utero may be helpful in iden-
tifying the initiating pathways that are activated during the
early phases.
The increased activation of caspase-3 in the CF pig
pancreas suggests that apoptosis is a component of
pancreatic injury in CF; however, its role as a primary
cause or secondary mediator is unclear. Apoptosis is a
prominent component of the acute inflammatory phase of
injury, and correlates with the degree of damage and
injury in several models.50
The presence of activated classical and alternative
complement pathways in the fetal and newborn CF pan-
creas is intriguing and not previously described in hu-
mans with CF. Complement pathways may be activated
in acute pancreatitis, which then generate biologically
active peptides that mediate tissue injury.51–53 While
complement activation results in the massive amplifica-
tion and activation of the cell-killing membrane attack
complexes, it is interesting that the inhibitory stimuli (ie,
CD59 [protectin] or C1 inhibitor) failed to control the
activated complement pathways. It is not known whether
inhibition of the complement cascade might modify the
progressive tissue damage associated with pancreatic
disease in CF.
We found that mucous cell metaplasia, cell prolifera-
tion, and increased -SMA staining were observed in the
newborn CF pig pancreas but was lacking in fetuses.
Mucus is produced only by the epithelial cells of the
interlobular and main pancreatic ducts54,55; thus, in-
tralobular duct mucous cell metaplasia is pathognomonic
for pancreatic disease in CF.15,17 The presence of mu-
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pigs, but not fetuses, suggests that mucous cell meta-
plasia was a response to chronic destruction and inflam-
mation of the pancreas, rather than an initiating event.
Likewise, we observed prominent cell proliferation in the
newborn CF pig pancreas, which was lacking in the fe-
tuses. Duct cell proliferation is a common response to
chronic injury or obstruction,56–59 and the presence of
increased cellular proliferation in the CF pancreas at birth
would be consistent with this premise. -SMA, a marker
of myofibroblast and activation of early pathways of fibro-
sis,44 was present in both fetal and newborn CF pig
pancreas; however, overt fibrosis in the CF pig pancreas
was not observed until weeks to months after birth.46,60
Considered together, these data highlight the progres-
sive nature of pancreatic disease in CF and support our
hypothesis that the tissue remodeling processes are late
events in CF pathogenesis.
In summary, pancreatic inflammation and damage
starts in utero in CF pigs, and advances over time to
severe destruction of the organ. Inflammation and degen-
erative changes to acini are characteristic in both fetal
and newborn pig pancreas. Mucous cell metaplasia and
duct cell proliferation were present in newborn but not
fetal pancreas, which suggests that they do not have a
major role in the pathogenesis of the disease but repre-
sent a late response to ongoing tissue inflammation and
damage. The pathways described in the present study
may contribute to the pathogenesis of pancreatic disease
in CF and may represent possible targets for modifying
the disease course in future studies.
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